Polycystic Ovarian Syndrome Market Research Report Information By Diagnosis (Pelvic Examination, Ultrasound, Blood Tests), Treatment ([Oral Contraceptives, Antiandrogens, Insulin Sensitizing Agent, Antidepressant, Anti-Obesity, Surgery {Ovarian Wedge Resection and Laparoscopic Ovarian Drilling}]), End-User (Hospitals & Clinics, Ambulatory Surgical Centers), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

Global Polycystic Ovarian Syndrome Market Overview

Polycystic Ovarian Syndrome Market Size was valued at USD 2.93 Billion in 2023. The Polycystic Ovarian Syndrome industry is projected to grow from USD 3.08 Billion in 2024 to USD 4.26 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.89% during the forecast period (2024 - 2032).The rising frequency of diabetes, the use of less invasive surgery, and the rise in female hormonal diseases are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

For September 2023, Ulike, the market leader in home IPL hair removal, is supporting Polycystic Ovary Syndrome (PCOS) warriors for PCOS Awareness Month (September) through their We See You campaign. This has been Ulike’s mission for years: raising Hirsutism awareness as well as giving patients alternatives that are sympathetic to it for a category of women who have PCOS and experience undesired growth of body and facial hair in particular. The company’s most recent introduction, Air3, boasts advanced patented techniques that enable smooth and effective hair removal. Thus, the brand combines science with user-centered design, ensuring both safety and effectiveness and providing visible results within a short time span of three weeks only. In addition to that, long-lasting smoothness also pleases PCOS users since the latter normally experience faster hair re-growth than an average woman does.

BioSyent Inc. (“BioSyent”, TSX Venture: RX) wishes to announce in August 2023 that its child company, BioSyent Pharma Inc., has made its first shipments of Inofolic® into the Canadian markets. Living with PCOS can find myo-inositol with folic acid in one special soft-gel capsule called Inofolic®, A natural health product designed for females suffering from polycystic ovarian syndrome-PCOS). As many as 1.4 million Canadian women have endocrine disorders, i.e., a syndrome known as polycystic ovary syndrome (PCOS). Its causative agents concerning this include insulin resistance problems leading to infertility, menstrual dysfunction, among others, acne outbreaks, and hirsutism-related skin effects caused by excess body hair growth over men’s faces or chins.

Rachel Blank did not always get along with hormones in June 2021; she had a history with them, too. After she left General Catalyst, where Ms Blank worked as an investor to join Ro, a startup they had been backing from the seed stage, she was in charge of growing Rory. Nonetheless, her decision to leave the director’s role at a health technology unicorn valued at $5 billion and set up her own company for women’s hormonal health. Today, the startup is coming out of stealth with millions in venture-backing and more than 35,000 women in its community. An early-stage New York-based startup called Allara looks to help women struggling with polycystic ovary syndrome (PCOS) better manage it. It leads to irregular periods or difficulty getting pregnant in females, as well as acne and obesity with unwanted hair growth. And it is not uncommon, affecting around one out of every ten women who can have children.

Polycystic ovarian syndrome Market Trends

• A Rise in the frequency of and knowledge of polycystic ovarian syndrome among patients will boost market growth.

An increase in polycystic ovarian syndrome prevalence, patient population awareness, and the use of combination therapy drives the growth of the polycystic ovarian syndrome treatment market. Additionally, the market growth is influenced by the ease of access to polycystic ovarian syndrome therapies, increased demand for polycystic ovarian syndrome drugs, and technological developments for cancer screening. However, the absence of authorized treatments and the unclear pathophysiology and etiology of the polycystic ovarian syndrome are expected to restrain market expansion. Additionally, throughout the anticipated time, the emerging countries' untapped potential offers profitable chances for the expansion of the polycystic ovarian syndrome treatment market. However, the absence of specialized therapy for polycystic ovarian syndrome disease is anticipated to impede the expansion of the industry. The need for polycystic ovarian syndrome treatment drugs is anticipated to increase as polycystic ovarian syndrome becomes more common. For instance, according to the Centers for Disease Control and Prevention, the polycystic ovarian syndrome affects 6 to 12% (or as many as 5 million) of American women of reproductive age. It is one of the most prevalent reasons for female infertility. Due to the rising prevalence of co-morbid illnesses, including diabetes and obesity, more people have PCOS. Thus, this factor is driving the market CAGR.

Over the projected period, it is also anticipated that increasing spending on R&D activities and the release of innovative medications would spur market expansion for pharmaceuticals treating polycystic ovary syndrome. However, a shortage of FDA-approved medications, a lack of polycystic ovarian syndrome awareness in developing nations, and rising adverse effects from generic medications might restrain market expansion throughout the projection period.

The market is anticipated to be driven by several government and private sector efforts to raise awareness of the illness. For example, in June 2020, research funded by the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Diabetes and Digestive and Kidney Diseases, titled "Different subtypes of polycystic ovarian syndrome with new genetic associations: An unsupervised, phenotypic clustering analysis," revealed that polycystic ovary syndrome might have at least two distinct subtypes. Thus, it is anticipated that this aspect will accelerate polycystic ovarian syndrome  market revenue globally.

Polycystic Ovarian Syndrome Market Segment Insights

Polycystic Ovarian Syndrome Diagnosis Insights

Based on Diagnosis, the global polycystic ovarian syndrome market segmentation includes a pelvic examination, ultrasound, and blood tests. The ultrasound segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032.  ovaries condition and the thickness of your uterus' lining may be examined with an ultrasound. Your vagina receives a transducer, which resembles a wand. Sound waves released by the transducer are converted into visuals on a computer screen.

Figure1: Polycystic Ovarian Syndrome Market, by Diagnosis, 2023 & 2032 (USD Million)\Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Polycystic Ovarian Syndrome Treatment Insights

The global polycystic ovarian syndrome market segmentation, based on Treatment, includes Oral Contraceptives, Antiandrogens, Insulin Sensitizing Agent, Antidepressant, Anti-Obesity, Surgery (Ovarian Wedge Resection and Laparoscopic Ovarian Drilling). The surgery segment held the majority share in 2022 in the global Polycystic ovarian syndrome market data One of the most frequent operations surgeons perform in life-threatening situations is laparoscopic ovarian drilling (LOD). Since polycystic ovarian syndrome is a key contributing factor to women's reproductive issues and treatment response deteriorates over time, abdominal surgery using a thin microscope is highly preferred globally.

According to research published in the Cochrane Library in July 2020 under the title "Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome," if the chance of a live birth following medical ovulation induction alone is 42%, the chance of a live birth following LOD is between 28% and 40%. According to the study, laparoscopic drilling is highly likely to succeed in women, which is why it is the procedure of choice. Patients are drawn to this surgical technique due to its simplicity of illness treatment and cost-effectiveness. As a result, it is predicted to have a sizable share throughout the projection period.

Polycystic ovarian syndrome End-user Insights

Based on End-user, the global polycystic ovarian syndrome market segmentation includes Hospitals & Clinics and Ambulatory Surgical Centers. The Hospitals & Clinics segment dominated the Polycystic ovarian syndrome  market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. In 2021, Ambulatory Surgical Centers ranked second in terms of market size. Due to the present rise in polycystic ovarian syndrome incidence and the rising number of procedures performed in hospital settings, the hospital segment is predicted to develop at the quickest rate. Polycystic ovarian syndrome is often diagnosed and treated in hospitals. Since no one test can be used to precisely identify polycystic ovarian syndrome (PCOS), clinicians must determine this for patients with the polycystic ovarian syndrome.

Polycystic Ovarian Syndrome Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. In North America, the Polycystic ovarian syndrome market accounted for USD 1.3 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. One of the major reasons driving the market growth in North America is the rise in polycystic ovarian syndrome cases due to rising rates of obesity and overweight. In addition, more people are becoming aware of the advantages of routine checkups, increasing the number of new cases detected here each year. The United States dominates the North American Polycystic ovarian syndrome market with the highest revenue share. This market is expanding mostly due to this nation's huge number of polycystic ovarian syndrome sufferers. Furthermore, the U.S.'s ability to attract large market participants like Merck, Abbott, and BMS would substantially impact the nation's ability to generate income.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: POLYCYSTIC OVARIAN SYNDROME  MARKET SHARE BY REGION 2021 (%)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Asia Pacific Polycystic ovarian syndrome Market together make up most of the population in the Asia Pacific region. As a result, the Region's polycystic ovarian syndrome treatment market has tremendous development potential due to the presence of a sizable target patient pool. The governments of these nations are concentrating on reducing the rising prevalence of polycystic ovarian syndrome by implementing initiatives that promote the Diagnosis, Treatment, and necessary lifestyle change of this syndrome. These initiatives raise public awareness of the polycystic ovarian syndrome and its hazards, including the emergence of insulin resistance, obesity, and occasionally infertility. Shortly, the Asia Pacific market is anticipated to be driven by these reasons. Further, the China Polycystic ovarian syndrome  market held the largest market share, and the India Polycystic ovarian syndrome  market was the fastest growing market in the region.

Due to improvements in healthcare infrastructure, an increase in the number of target populations, a growing R&D sector, an increase in healthcare reforms, and technical developments in the healthcare field, Europe Polycystic ovarian syndrome Market will have the third-highest growth during the projected period of 2021. Moreover, U.K. Polycystic ovarian syndrome Market held the largest market share, and the Germany Polycystic ovarian syndrome  Market was the fastest-growing market in the Region.

Polycystic ovarian syndrome  Key Market Players & Competitive Insights

Major market players are investing a lot of money in R&D to expand their product portfolios, which will spur further market growth for cervical fusion. With significant industry changes, including new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their global presence. To grow and remain in a market that is becoming more and more competitive, polycystic ovarian syndrome industry competitors must provide affordable products.

Manufacturing locally to cut operational costs is one of the main business tactics used by the Polycystic ovarian syndrome industry to serve customers and increase the market sector. The Polycystic ovarian syndrome industry has recently given medicine some of the most important advantages. The Polycystic ovarian syndrome market major player such as Bayer AG, AstraZeneca plc, Abbott, Biocinese, Catalysis, S.L., Crinetics Pharmaceuticals, Inc., Sanofi, Eugonia, EffRx, Inc., Ferring Pharmaceuticals, Inc., Merck KGaA, Bristol-Myer Squibb Company, Neurocrine Biosciences, Inc., Reliance Life Sciences Pvt. Ltd. Pfizer, Inc., Novartis AG, and Shire Plc., and others are working to expand the market demand by investing in research and development activities.

Founded in 2013, the American biopharmaceutical business AbbVie is publicly listed. It began as an Abbott Laboratories spin-off. Abbvie was conducting a clinical study in women with polycystic ovarian syndrome to determine the safety and effectiveness of the drug Elagolix January 2020. Elagolix's safety and effectiveness in treating women with Polycystic ovarian syndrome are now being examined in a Phase 2 multicenter, double-blind, randomized, placebo-controlled study being carried out by the company (PCOS).

One of the biggest pharmaceutical firms in the world is Bayer AG, a global German pharmaceutical and biotechnology corporation. • In January 2020, Evotec S.E. and Bayer AG announced the start of a new, multi-target, five-year cooperation with Celmatix Inc. to develop several clinical candidates for the management of polycystic ovarian syndrome, which is anticipated to dominate the market for the whole forecast period. In January 2020, Abbvie will begin a clinical trial employing the drug Elagolix, which is being tested for both safety and effectiveness in treating Polycystic ovarian syndrome in female patients. Elagolix's safety and effectiveness in treating women with polycystic ovarian syndrome are being examined in the Phase 2 multicenter, double-blind, randomized, placebo-controlled study that the company is now doing.

Key Companies in the polycystic ovarian syndrome market include

• Bayer AG


• AstraZeneca plc


• Abbott, Biocinese


• Catalysis, S.L.


• Crinetics Pharmaceuticals, Inc.


• Sanofi, Eugonia, EffRxnInc.


• Ferring Pharmaceuticals Inc.


• Merck KGaA


• Bristol-Myer Squibb Company


• Neurocrine Biosciences Inc.


• Reliance Life Sciences Pvt. Ltd.


• Pfizer, Inc.


• Novartis AG


• Shire Plc.

Polycystic Ovarian Syndrome Industry Developments

• December 2021 A global provider of women's healthcare, Organon, purchased Forendo Pharma, a firm specializing in clinical-stage medication development for women's health. A polycystic ovarian syndrome-focused preclinical program is part of Forendo's pipeline (PCOS).


• January 2020 A new five-year multi-target partnership between Evotec S.E. and Bayer AG and Celmatix Inc. is underway to develop several clinical candidates for the management of polycystic ovarian syndrome, which is anticipated to dominate the market over the forecast period.


• January 2022 The ovarian biology-focused biotechnology business Celmatix Inc. announced the achievement of a third milestone in its five-year, multi-target partnership with Evotec. The achievement of the milestone of moving a Polycystic Ovarian Syndrome medication development built around a brand-new therapeutic target discovered by Celmatix towards hit identification was brought about by Evotec and Bayer AG.

Polycystic Ovarian Syndrome Market Segmentation

Polycystic Ovarian Syndrome Diagnosis Outlook

• Pelvic examination


• Transvaginal ultrasound


• Blood tests


• Hormone levels


• Glucose tolerance


• Cholesterol and triglyceride levels

Polycystic Ovarian Syndrome Treatment Outlook

• Oral Contraceptives


• Antiandrogens


• Insulin Sensitizing Agent


• Antidepressant


• Anti-Obesity


• Surgery


• Ovarian Wedge Resection


• Laparoscopic Ovarian Drilling

Polycystic Ovarian Syndrome End-User Outlook

• Hospitals & Clinics


• Ambulatory Surgical Centers


• Diagnostic Centers


• Gynecology Centers


• Feminist Health Centers

Polycystic ovarian syndrome Regional Outlook

• 
  

  North America

  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  

  Europe

  
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  

  Asia-Pacific

  
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America